Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 1999, p. 1498-1507, Vol. 19, No. 2
National Cancer
Institute,1
Howard Hughes Medical
Institute
Received 20 February 1998/Returned for modification 14 April
1998/Accepted 30 October 1998
Rlk/Txk is a member of the BTK/Tec family of tyrosine kinases and
is primarily expressed in T lymphocytes. Unlike other members of this
kinase family, Rlk lacks a pleckstrin homology (PH) domain near the
amino terminus and instead contains a distinctive cysteine string
motif. We demonstrate here that Rlk protein consists of two isoforms
that arise by alternative initiation of translation from the same cDNA.
The shorter, internally initiated protein species lacks the cysteine
string motif and is located in the nucleus when expressed in the
absence of the larger form. In contrast, the larger form is
cytoplasmic. We show that the larger form is palmitoylated and that
mutation of its cysteine string motif both abolishes palmitoylation and
allows the protein to migrate to the nucleus. The cysteine string,
therefore, is a critical determinant of both fatty acid modification
and protein localization for the larger isoform of Rlk, suggesting that
Rlk regulation is distinct from the other Btk family kinases. We
further show that Rlk is phosphorylated and changes localization in
response to T-cell-receptor (TCR) activation and, like the other Btk
family kinases, can be phosphorylated and activated by Src family
kinases. However, unlike the other Btk family members, Rlk is activated
independently of the activity of phosphatidylinositol 3-kinase,
consistent with its lack of a PH domain. Thus, Rlk has two distinct
isoforms, each of which may have unique properties in signaling
downstream from the TCR.
0270-7306/99/$00.00+0
rlk/TXK Encodes Two Forms of a Novel Cysteine String
Tyrosine Kinase Activated by Src Family Kinases

NIH Research Scholars Program,2
National Institute for Human Genome
Research,3 and
National Institute of
Allergy and Infectious Diseases,5 National
Institutes of Health, Bethesda, Maryland, and
George Washington
Institute of Biomedical Sciences, Washington,
D.C.4
*
Corresponding author. Mailing address: National Human
Genome Research Institute, 49/4A38, National Institutes of Health,
Bethesda, MD 20892-4472. Phone: (301) 435-1906. Fax: (301) 402-2170. E-mail: pams{at}nhgri.nih.gov.
Present address: Department of Pathology, Brigham and Women's
Hospital, Boston, MA 02115.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|